601127.SHG

Electric vehicle (EV) maker Seres Group Co. Ltd. (601127.SH) received regulatory approval from the China Securities Regulatory Commission (CSRC) for its planned Hong Kong IPO, according to a Thursday notice on the CSRC website. The announcement of the plan’s registration clears a key regulatory hurdle for the listing to move forward.

Seres plans to sell about 331 million shares in the IPO, which would complement its existing listing in Shanghai. The company previously filed a preliminary prospectus with the Hong Kong Stock Exchange in April.

Seres makes EVs under the Aito brand name. Its revenue quadrupled to 145 billion yuan ($20.3 billion) in 2024 from 35.8 billion yuan the previous year, as its gross margin rose to 23.8% from 7.2% over that period, according to the prospectus. The company became profitable in 2024 with a 5.9 billion yuan profit, making it only the world’s fourth new energy vehicle (NEV) maker to reach that milestone, according to the prospectus.

Seres’ Shanghai-listed stock rose 5.8% on Friday. Year-to-date the shares are up about 18%.

By Doug Young

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…